Whitehawk Therapeutics Net Income
| WHWK Stock | 2.86 0.01 0.35% |
As of the 16th of February 2026, Whitehawk Therapeutics maintains the Market Risk Adjusted Performance of 0.623, mean deviation of 3.32, and Downside Deviation of 3.75. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Whitehawk Therapeutics, as well as the relationship between them.
Whitehawk Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.4826 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -57.3 M | -60.2 M | |
| Net Loss | -57.3 M | -60.2 M | |
| Net Loss | (2.71) | (2.85) | |
| Net Income Per E B T | 1.15 | 1.10 |
Whitehawk | Net Income | Build AI portfolio with Whitehawk Stock |
Historical Net Income data for Whitehawk Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Whitehawk Therapeutics represents a compelling investment opportunity.
Latest Whitehawk Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Whitehawk Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Whitehawk Therapeutics financial statement analysis. It represents the amount of money remaining after all of Whitehawk Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Whitehawk Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Whitehawk Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (63.69 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Whitehawk Net Income Regression Statistics
| Arithmetic Mean | (31,976,335) | |
| Coefficient Of Variation | (96.40) | |
| Mean Deviation | 26,554,222 | |
| Median | (12,255,080) | |
| Standard Deviation | 30,825,425 | |
| Sample Variance | 950.2T | |
| Range | 106.6M | |
| R-Value | (0.70) | |
| Mean Square Error | 516.5T | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | (4,274,702) | |
| Total Sum of Squares | 15203.3T |
Whitehawk Net Income History
Other Fundumenentals of Whitehawk Therapeutics
Whitehawk Therapeutics Net Income component correlations
Whitehawk Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Whitehawk Therapeutics is extremely important. It helps to project a fair market value of Whitehawk Stock properly, considering its historical fundamentals such as Net Income. Since Whitehawk Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Whitehawk Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Whitehawk Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Whitehawk Therapeutics. Anticipated expansion of Whitehawk directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Whitehawk Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth 0.335 | Return On Assets | Return On Equity |
Investors evaluate Whitehawk Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Whitehawk Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Whitehawk Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Whitehawk Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Whitehawk Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Whitehawk Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Whitehawk Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Whitehawk Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Whitehawk Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Whitehawk Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Whitehawk Therapeutics or generate 0.0% return on investment in Whitehawk Therapeutics over 90 days. Whitehawk Therapeutics is related to or competes with Clene, MacroGenics, Immix Biopharma, Tevogen Bio, Ovid Therapeutics, Zentalis Pharmaceuticals, and Context Therapeutics. Whitehawk Therapeutics is entity of United States More
Whitehawk Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Whitehawk Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Whitehawk Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.75 | |||
| Information Ratio | 0.1007 | |||
| Maximum Drawdown | 21.49 | |||
| Value At Risk | (5.32) | |||
| Potential Upside | 6.98 |
Whitehawk Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Whitehawk Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Whitehawk Therapeutics' standard deviation. In reality, there are many statistical measures that can use Whitehawk Therapeutics historical prices to predict the future Whitehawk Therapeutics' volatility.| Risk Adjusted Performance | 0.1028 | |||
| Jensen Alpha | 0.4347 | |||
| Total Risk Alpha | 0.1706 | |||
| Sortino Ratio | 0.1124 | |||
| Treynor Ratio | 0.613 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Whitehawk Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Whitehawk Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1028 | |||
| Market Risk Adjusted Performance | 0.623 | |||
| Mean Deviation | 3.32 | |||
| Semi Deviation | 3.44 | |||
| Downside Deviation | 3.75 | |||
| Coefficient Of Variation | 851.82 | |||
| Standard Deviation | 4.19 | |||
| Variance | 17.55 | |||
| Information Ratio | 0.1007 | |||
| Jensen Alpha | 0.4347 | |||
| Total Risk Alpha | 0.1706 | |||
| Sortino Ratio | 0.1124 | |||
| Treynor Ratio | 0.613 | |||
| Maximum Drawdown | 21.49 | |||
| Value At Risk | (5.32) | |||
| Potential Upside | 6.98 | |||
| Downside Variance | 14.09 | |||
| Semi Variance | 11.83 | |||
| Expected Short fall | (3.71) | |||
| Skewness | 0.5488 | |||
| Kurtosis | 0.4406 |
Whitehawk Therapeutics Backtested Returns
Whitehawk Therapeutics appears to be risky, given 3 months investment horizon. Whitehawk Therapeutics shows Sharpe Ratio of 0.13, which attests that the company had a 0.13 % return per unit of risk over the last 3 months. By examining Whitehawk Therapeutics' technical indicators, you can evaluate if the expected return of 0.55% is justified by implied risk. Please utilize Whitehawk Therapeutics' Mean Deviation of 3.32, downside deviation of 3.75, and Market Risk Adjusted Performance of 0.623 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Whitehawk Therapeutics holds a performance score of 10. The firm maintains a market beta of 0.79, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Whitehawk Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Whitehawk Therapeutics is expected to be smaller as well. Please check Whitehawk Therapeutics' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Whitehawk Therapeutics' historical returns will revert.
Auto-correlation | 0.49 |
Average predictability
Whitehawk Therapeutics has average predictability. Overlapping area represents the amount of predictability between Whitehawk Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Whitehawk Therapeutics price movement. The serial correlation of 0.49 indicates that about 49.0% of current Whitehawk Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.49 | |
| Spearman Rank Test | 0.42 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Whitehawk Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Whitehawk Therapeutics reported net income of (63.69 Million). This is 118.66% lower than that of the Biotechnology sector and 190.93% lower than that of the Health Care industry. The net income for all United States stocks is 111.15% higher than that of the company.
Whitehawk Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Whitehawk Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Whitehawk Therapeutics could also be used in its relative valuation, which is a method of valuing Whitehawk Therapeutics by comparing valuation metrics of similar companies.Whitehawk Therapeutics is currently under evaluation in net income category among its peers.
Whitehawk Fundamentals
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.54 | ||||
| Profit Margin | (1.09) % | ||||
| Operating Margin | (7.54) % | ||||
| Current Valuation | (28.28 M) | ||||
| Shares Outstanding | 47.13 M | ||||
| Shares Owned By Insiders | 12.43 % | ||||
| Shares Owned By Institutions | 67.38 % | ||||
| Number Of Shares Shorted | 847.43 K | ||||
| Price To Book | 0.85 X | ||||
| Price To Sales | 9.34 X | ||||
| Revenue | 25.98 M | ||||
| Gross Profit | (73.45 M) | ||||
| EBITDA | (64.63 M) | ||||
| Net Income | (63.69 M) | ||||
| Total Debt | 833 K | ||||
| Book Value Per Share | 3.33 X | ||||
| Cash Flow From Operations | (59.55 M) | ||||
| Short Ratio | 7.45 X | ||||
| Earnings Per Share | (0.64) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 22 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 134.32 M | ||||
| Total Asset | 70.32 M | ||||
| Retained Earnings | (332.65 M) | ||||
| Working Capital | 44.21 M | ||||
| Net Asset | 70.32 M |
About Whitehawk Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Whitehawk Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Whitehawk Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Whitehawk Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Whitehawk Stock please use our How to buy in Whitehawk Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Whitehawk Therapeutics. Anticipated expansion of Whitehawk directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Whitehawk Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth 0.335 | Return On Assets | Return On Equity |
Investors evaluate Whitehawk Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Whitehawk Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Whitehawk Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Whitehawk Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Whitehawk Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Whitehawk Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.